OptiBiotix Health PLC OPTI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 16.50
- Day Range
- GBX 16.32–17.50
- 52-Week Range
- GBX 14.07–35.00
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 1.64 Bil
- Volume/Avg
- 49,665 / 529,460
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 25.18
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
OptiBiotix Health PLC is engaged in the field of healthcare. As a life science company, its prime focus lies in researching the area of biotechnology. Its activities include the identification of microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology, deriving potential health benefits. The company derives majority of the revenue from the sale of Functional Fibres. The company markets its products in the United Kingdom under trademark names such as OptiBiotix, SweetBiotix, and SkinBioTherapeutics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 5
- Website
- https://www.optibiotix.com
Valuation
|
Metric
|
OPTI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.86 |
Price/Sales | 25.18 |
Price/Cash Flow | — |
Price/Earnings
OPTI
Financial Strength
|
Metric
|
OPTI
|
|---|---|
Quick Ratio | 6.62 |
Current Ratio | 7.67 |
Interest Coverage | — |
Quick Ratio
OPTI
Profitability
|
Metric
|
OPTI
|
|---|---|
Return on Assets (Normalized) | −19.45% |
Return on Equity (Normalized) | −22.94% |
Return on Invested Capital (Normalized) | −20.84% |
Return on Assets
OPTI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Rqlqrdzbg | Ndbm | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jcqbzybbp | Nnjzm | $119.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jzslvmvz | Mzlgbg | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gfnnjhzl | Gxdtrl | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Wkqgszb | Xbf | $32.5 Bil | |||
| BioNTech SE ADR
BNTX
| Jsfdssdc | Ywdh | $28.0 Bil | |||
| Moderna Inc
MRNA
| Xckdyjsv | Drrx | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Wpmfzhmq | Hhzky | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ydkbjtgvc | Lffhs | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Tfkcppzcl | Cyjplzv | $12.6 Bil |
United States